What is the appropriate treatment for a three‑month Candida albicans infection that has not responded to several weeks of fluconazole therapy?

Switch to an Echinocandin Immediately

For a 3-month Candida albicans infection unresponsive to several weeks of fluconazole, you should switch to an echinocandin (caspofungin, micafungin, or anidulafungin) as first-line salvage therapy. This represents either treatment failure from fluconazole-resistant C. albicans or inadequate drug levels, and continuing azole therapy risks further clinical deterioration and mortality.

Clinical Approach

Immediate Actions

1. Switch antifungal class immediately - Do not continue fluconazole or try another azole first

   • Echinocandin options 1, 2:
     • Caspofungin: 70 mg loading dose, then 50 mg daily
     • Micafungin: 100 mg daily
     • Anidulafungin: 200 mg loading dose, then 100 mg daily

2. Obtain susceptibility testing - Send isolates for antifungal susceptibility testing to confirm fluconazole resistance and guide subsequent therapy 1, 3

3. Identify the infection site - The treatment duration and approach differs dramatically:

   • Mucosal disease (oropharyngeal/esophageal): Consider itraconazole solution 200 mg daily or posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily for fluconazole-refractory disease 1
   • Invasive/bloodstream infection: Echinocandin for 2 weeks after blood culture clearance 1, 2
   • CNS involvement: Amphotericin B deoxycholate 1 mg/kg IV daily or liposomal amphotericin B 5 mg/kg daily, with or without flucytosine 25 mg/kg four times daily 1, 4

Why Echinocandins Over Continuing Azoles

The evidence strongly supports this switch:

• Echinocandins are fungicidal against C. albicans, while fluconazole is only fungistatic 5, 6
• Anidulafungin demonstrated superior efficacy over fluconazole for C. albicans infections (81.1% vs 62.3% global response), with significantly faster blood culture clearance 5
• Fluconazole resistance in C. albicans, while historically uncommon, is increasingly documented - one referral center found 7.3% clinical resistance rates 7, 8
• After 3 months of failed therapy, you must assume either resistance or inadequate drug exposure

Alternative Considerations

For mucosal infections only (oropharyngeal/esophageal candidiasis):

• Itraconazole solution 200 mg once daily 1
• Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily 1
• Voriconazole 200 mg twice daily 1
• Amphotericin B deoxycholate oral suspension (must be compounded) 1

For invasive disease with CNS involvement:

• Liposomal amphotericin B 5 mg/kg daily is strongly recommended over echinocandins due to superior CNS penetration 1, 4
• Add flucytosine 25 mg/kg four times daily if available, though adverse effects are frequent 1

Critical Pitfalls to Avoid

1. Do not switch to voriconazole or another azole first - Cross-resistance is likely if fluconazole has failed for this duration 6

2. Do not use echinocandins for CNS infections - They have poor CNS penetration; amphotericin B formulations are required 4

3. Rule out metastatic complications - After 3 months of untreated/undertreated infection:

   • Obtain ophthalmologic examination for endophthalmitis 1
   • Consider imaging (CT/ultrasound) of liver, spleen, kidneys if bloodstream infection 1
   • Lumbar puncture if any CNS symptoms 1

4. Remove any indwelling catheters - Central venous catheter removal is strongly recommended and may be contributing to treatment failure 1, 2, 1

Duration of Therapy

• Mucosal disease: Treat for 7-14 days minimum after symptom resolution 1, 9
• Candidemia: Continue for 2 weeks after documented blood culture clearance and resolution of symptoms 1, 2, 1
• CNS infection: Continue until all signs, symptoms, CSF abnormalities, and radiological findings resolve - often months 1, 10

Step-Down Therapy

Only consider stepping down to fluconazole if:

• Susceptibility testing confirms fluconazole susceptibility (MIC ≤2 μg/mL)
• Patient is clinically stable
• Follow-up cultures are negative
• No CNS involvement 1, 2

The 3-month duration without response is highly concerning and suggests either significant resistance, inadequate source control, or unrecognized metastatic infection requiring aggressive intervention beyond simple drug substitution.